GlobeStar Therapeutics (GlobeStar Therapeutics) Interest Expense : $-0.09 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. GlobeStar Therapeutics's interest expense for the three months ended in Dec. 2023 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. GlobeStar Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -0.16 Mil. GlobeStar Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -0.01 Mil. GlobeStar Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

GlobeStar Therapeutics Interest Expense Historical Data

The historical data trend for GlobeStar Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Interest Expense Chart

GlobeStar Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Interest Expense

Get a 7-Day Free Trial

-0.36

-0.24

-0.29

-0.07

-0.09

GlobeStar Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.06	-0.01

GlobeStar Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

GlobeStar Therapeutics (OTCPK:GSTC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

GlobeStar Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-0.01 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-0.16 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.

GlobeStar Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GlobeStar Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

719 Jadewin Avenue, Richland, WA, USA, 99352

Website

https://www.globestarthera.com

GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.

Executives

James C Katzaroff	director, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
William J Farley	director	468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski	officer: CFO	145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship	director, officer: CEO, Pres., Secr., Treas.	14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood	10 percent owner	5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau	director	770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer	director	1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz	director, officer: Interim CEO & Chairman	495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550